Positive PhIII results in hand, Concert Pharma forges ahead with NDA and commercialization plans for hair loss drug

Concert Pharmaceuticals has been waiting to tout Phase III data amidst a sell-off of the bulk of its pipeline to Terran Biosciences and several other events for the biotech. And on Monday, the company rolled out the red carpet.

Concert unveiled topline results from its second Phase III clinical...

Click to view original post